Family Medicine Doctors in Hamlin, WV Accepting Medicare

3 Family Medicine doctors found. Showing 1 - 3

Charles Vance Iii, DO Family Medicine Medicare: Medicare Enrolled Practice Location: 7400 Lynn Ave, Hamlin, WV 25523 Phone: 304-824-5806    Fax: 304-824-5804

Gregory A Elkins, MD Family Medicine - Sports Medicine Medicare: Accepting Medicare Assignments Practice Location: 7400 Lynn Ave, Hamlin, WV 25523 Phone: 304-824-5806    Fax: 304-824-5885

Laura Given, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 7400 Lynn Ave, Hamlin, WV 25523 Phone: 304-824-5806    Fax: 304-824-5885

News Archive

Study identifies how BPA may encourage inflammatory breast cancer growth

The chemical bisphenol A, or BPA, appears to aid the survival of inflammatory breast cancer cells, revealing a potential mechanism for how the disease grows, according to a study led by researchers in the Department of Surgery at Duke University School of Medicine and the Duke Cancer Institute.

Concentric Medical commences TREVO Study of Stentriever technology in ischemic stroke patients

Concentric Medical, Inc., the global leader in acute ischemic stroke intervention, today announced the start of the TREVO Study. The first patients were enrolled and successfully treated at the Hospital Clinic de Barcelona by the Neuroradiology team of Drs. Juan Macho and Jordi Blasco.

Otsuka Pharmaceutical acquires newly issued common shares of MethylGene

Otsuka Pharmaceutical Co., Ltd., a wholly owned subsidiary of Otsuka Holdings Co., Ltd. based in Japan, announces that on October 20, 2009, pursuant to the private placement disclosed on October 14, 2009, it acquired 3,686,182 newly issued common shares of MethylGene Inc. Following the closing of this private placement, Otsuka Pharmaceutical owns 9.12% of the issued and outstanding common shares of MethylGene.

Boehringer Ingelheim disappointed with FDA Advisory Committee recommendations on flibanserin NDA for HSDD

The Reproductive Health Drugs Advisory Committee met today to discuss the new drug application (NDA) for flibanserin 100 mg as a treatment for Hypoactive Sexual Desire Disorder (HSDD) in pre-menopausal women. The advisory committee was convened by and makes recommendations to the U.S. Food and Drug Administration (FDA). The FDA will consider the committee's advice as part of its final assessment of the NDA.

Enrollment complete in Nabi's first NicVAX Phase III clinical trial for nicotine addiction

Nabi Biopharmaceuticals announced today that it has completed enrollment in the first Phase III clinical trial of NicVAX® (Nicotine Conjugate Vaccine), the company's innovative and proprietary investigational vaccine being developed to treat nicotine addiction and prevent smoking relapse.

Read more Medical News

› Verified 7 days ago